In the British pharmaceutical industry, there were 33 M&A deals announced in Q4 2023, worth a total value of $779.7m, according to GlobalData’s Deals Database. The $477.6m acquisition of Orchard Therapeutics by Kyowa Kirin was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in the UK decreased by 91% in Q4 2023 compared with the previous quarter’s total of $8.6bn and fell by 74% as compared to Q4 2022. Related deal volume increased by 14% in Q4 2023 versus the previous quarter and was 27% higher than in Q4 2022.
The top-ranked financial advisors supporting these M&A deals in the UK in Q4 2023 were Barclays; Investec; Mizuho Financial Group with 3, 2, 2 deals respectively.
The top-ranked legal advisorss supporting these M&A deals in the UK Q4 2023 were Addleshaw Goddard; Ashurst; Gibson, Dunn & Crutcher with 4, 4, 4 deals respectively.
See Also:
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in 2023 – Thematic Intelligence, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.